{
  "SOPA": [
    {
      "author": "Benzinga Insights",
      "content": "",
      "created_at": "2025-02-11T17:30:27Z",
      "headline": "Peering Into Society Pass's Recent Short Interest",
      "id": 43633166,
      "images": [
        {
          "size": "large",
          "url": "https://cdn.benzinga.com/files/imagecache/2048x1536xUP/images/story/2023/movers_image_5.jpeg"
        },
        {
          "size": "small",
          "url": "https://cdn.benzinga.com/files/imagecache/1024x768xUP/images/story/2023/movers_image_5.jpeg"
        },
        {
          "size": "thumb",
          "url": "https://cdn.benzinga.com/files/imagecache/250x187xUP/images/story/2023/movers_image_5.jpeg"
        }
      ],
      "source": "benzinga",
      "summary": " ",
      "symbols": [
        "SOPA"
      ],
      "updated_at": "2025-02-11T17:30:27Z",
      "url": "https://www.benzinga.com/insights/short-sellers/25/02/43633166/peering-into-society-passs-recent-short-interest",
      "added_at": "2025-02-12T08:54:02.953Z"
    }
  ],
  "AIFF": [],
  "LIPO": [
    {
      "author": "Vandana Singh",
      "content": "",
      "created_at": "2025-02-11T15:52:36Z",
      "headline": "Nano Cap Lipella Pharmaceuticals Stock Jumps On Positive Trial Data In Patients With Sore Mouth Membranes",
      "id": 43629227,
      "images": [
        {
          "size": "large",
          "url": "https://cdn.benzinga.com/files/imagecache/2048x1536xUP/images/story/2025/02/11/LIPO.png"
        },
        {
          "size": "small",
          "url": "https://cdn.benzinga.com/files/imagecache/1024x768xUP/images/story/2025/02/11/LIPO.png"
        },
        {
          "size": "thumb",
          "url": "https://cdn.benzinga.com/files/imagecache/250x187xUP/images/story/2025/02/11/LIPO.png"
        }
      ],
      "source": "benzinga",
      "summary": "Lipella&#39;s LP-310 Phase 2a trial showed strong efficacy and safety for oral lichen planus. The company plans a Phase 2b trial and an FDA designation request in 2025.",
      "symbols": [
        "LIPO"
      ],
      "updated_at": "2025-02-11T15:52:36Z",
      "url": "https://www.benzinga.com/25/02/43629227/nano-cap-lipella-pharmaceuticals-stock-jumps-on-positive-trial-data-in-patients-with-sore-mouth-membranes",
      "added_at": "2025-02-12T08:54:02.953Z"
    },
    {
      "author": "Benzinga Newsdesk",
      "content": "",
      "created_at": "2025-02-11T10:49:42Z",
      "headline": "Lipella Pharmaceuticals Shares Phase 2a Results For LP-310 In The Treatment Of Oral Lichen Planus, Showing Favorable Safety Profile And Tolerability Of Twice-Daily Oral Rinse",
      "id": 43617270,
      "images": [],
      "source": "benzinga",
      "summary": "",
      "symbols": [
        "LIPO"
      ],
      "updated_at": "2025-02-11T10:49:42Z",
      "url": "https://www.benzinga.com/general/health-care/25/02/43617270/lipella-pharmaceuticals-shares-phase-2a-results-for-lp-310-in-the-treatment-of-oral-lichen-pl",
      "added_at": "2025-02-12T08:54:02.953Z"
    }
  ],
  "LTRY": [
    {
      "author": "Benzinga Newsdesk",
      "content": "",
      "created_at": "2025-02-11T12:48:42Z",
      "headline": "Lottery.com's Brand Sports.com Inks Multi-Year Partnership Agreement With Soccerex",
      "id": 43620340,
      "images": [],
      "source": "benzinga",
      "summary": "",
      "symbols": [
        "LTRY"
      ],
      "updated_at": "2025-02-11T12:48:43Z",
      "url": "https://www.benzinga.com/general/entertainment/25/02/43620340/lottery-coms-brand-sports-com-inks-multi-year-partnership-agreement-with-soccerex",
      "added_at": "2025-02-12T08:54:02.953Z"
    }
  ],
  "ANAB": [
    {
      "author": "Benzinga Newsdesk",
      "content": "",
      "created_at": "2025-02-12T12:31:38Z",
      "headline": "AnaptysBio's Rosnilimab Shows Results for Rheumatoid Arthritis, Hits Key Endpoints in Phase 2b Trial",
      "id": 43654073,
      "images": [],
      "source": "benzinga",
      "summary": "",
      "symbols": [
        "ANAB"
      ],
      "updated_at": "2025-02-12T12:31:39Z",
      "url": "https://www.benzinga.com/news/25/02/43654073/anaptysbios-rosnilimab-shows-results-for-rheumatoid-arthritis-hits-key-endpoints-in-phase-2b-trial",
      "added_at": "2025-02-12T13:55:19.119Z"
    }
  ],
  "XLO": [
    {
      "author": "Benzinga Newsdesk",
      "content": "",
      "created_at": "2025-02-12T12:39:03Z",
      "headline": "Xilio Therapeutics Announced Three Wholly-owned Preclinical Programs For Masked T Cell Engagers Targeting Prostate-specific Membrane Antigen, Claudin 18.2 And Six-transmembrane Epithelial Antigen Of Prostate 1",
      "id": 43654329,
      "images": [],
      "source": "benzinga",
      "summary": "",
      "symbols": [
        "XLO"
      ],
      "updated_at": "2025-02-12T12:39:03Z",
      "url": "https://www.benzinga.com/news/25/02/43654329/xilio-therapeutics-announced-three-wholly-owned-preclinical-programs-for-masked-t-cell-engagers-targ",
      "added_at": "2025-02-12T13:55:19.119Z"
    }
  ],
  "NEUP": [],
  "ANRO": [
    {
      "author": "Benzinga Newsdesk",
      "content": "",
      "created_at": "2025-02-12T13:07:51Z",
      "headline": "Alto Neuroscience Says Based On Results Of Interim Analysis, ALTO-300 Phase 2b Trial Will Continue With An increase Of ~50 Biomarker Positive Patients, With Topline Results Expected In Mid 2026",
      "id": 43655377,
      "images": [],
      "source": "benzinga",
      "summary": "",
      "symbols": [
        "ANRO"
      ],
      "updated_at": "2025-02-12T13:07:52Z",
      "url": "https://www.benzinga.com/general/biotech/25/02/43655377/alto-neuroscience-says-based-on-results-of-interim-analysis-alto-300-phase-2b-trial-will-continue",
      "added_at": "2025-02-12T13:55:19.330Z"
    }
  ],
  "XTIA": [
    {
      "author": "Benzinga Newsdesk",
      "content": "",
      "created_at": "2025-02-12T14:02:03Z",
      "headline": "XTI Aerospace Regains Nasdaq Compliance",
      "id": 43657611,
      "images": [],
      "source": "benzinga",
      "summary": "",
      "symbols": [
        "XTIA"
      ],
      "updated_at": "2025-02-12T14:02:03Z",
      "url": "https://www.benzinga.com/news/25/02/43657611/xti-aerospace-regains-nasdaq-compliance",
      "added_at": "2025-02-12T14:05:48.721Z"
    }
  ]
}